We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 46

Canada’s Federal Court of Appeal limits damages available to delayed generics
  • Torys LLP
  • Canada
  • June 8 2009

On June 4, 2009, in Merck Frosst Canada Inc. v. Apotex, Inc., the Federal Court of Appeal released an important decision limiting the range of damages available in actions under section 8 of the Patented Medicines (Notice of Compliance) Regulations


Ontario court confirms generic drug manufacturers not entitled to unjust enrichment
  • Torys LLP
  • Canada
  • January 22 2013

On January 15, 2013, the Ontario Superior Court of Justice (Ontario Court) granted a motion for partial summary judgment in Apotex Inc. v. Abbott


Canada's approach to functional foods
  • Torys LLP
  • Canada
  • April 21 2010

Today’s diet- and health-conscious environment has led to a proliferation of functional food marketing claims that advertise the specific health-enhancing characteristics of a food product


Product liability litigation: bar raised for class action certification?
  • Torys LLP
  • Canada
  • May 10 2012

In a decision released May 7, 2012, Justice Caroline Horkins of the Superior Court of Ontario has refused to certify a proposed class proceeding in a pharmaceutical product liability claim (Martin et al. v. Astrazeneca Pharmaceuticals PLC et al


Supreme Court of Canada rules on data protection for drug innovators
  • Torys LLP
  • Canada
  • February 8 2012

On February 3, 2012, the Supreme Court of Canada released its long-awaited decision in Merck Frosst Canada Ltd. v. Canada (Health), the culmination of over a decade of litigation between Merck and the Minister of Health


Canada amends regulations on adverse drug reaction reporting
  • Torys LLP
  • Canada
  • March 11 2011

Amended regulations regarding the reporting of adverse drug reactions came into force on February 10, 2011


Deadline for compliance of medical device software in Canada: February 1, 2011
  • Torys LLP
  • Canada
  • January 17 2011

The Medical Devices Bureau of Health Canada (the Bureau) expects that all Class I Medical Device software marketed in Canada will be compliant with the Medical Devices Regulations (the Regulations) by February 1, 2011, and all Class II Medical Device software will be compliant by September 1, 2011


Proposed amendment would exempt some generic submissions from Canada’s PM(NOC) regulations
  • Torys LLP
  • Canada
  • October 4 2011

Health Canada has released a proposed amendment to its guidance document Patented Medicines (Notice of Compliance) Regulations


Changes in the regulation of energy drinks in Canada
  • Torys LLP
  • Canada
  • October 18 2011

On October 6, 2011, Health Canada announced its decision to begin regulating most energy drinks as foods


Follow-on biologics in Canada: a look at the new draft guidelines
  • Torys LLP
  • Canada
  • May 27 2008

Health Canada has released a draft guidance document entitled “Information and Submission Requirements for Subsequent Entry Biologics (SEBs).”